Amneal Pharmaceuticals (AMRX) EBIT (2017 - 2026)

Amneal Pharmaceuticals' EBIT history runs 10 years deep, the most recent figure standing at $141.8 million for Q1 2026.

• In Q1 2026, EBIT rose 41.28% year-over-year to $141.8 million; the TTM figure through Mar 2026 stood at $435.5 million (up 20.84% YoY), while the FY2025 annual figure was $394.1 million, up 58.06% from the prior year.
• EBIT was $141.8 million for Q1 2026 at Amneal Pharmaceuticals, up from $112.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $141.8 million in Q1 2026 to a low of -$198.6 million in Q2 2022.
• Historically, EBIT has averaged $52.6 million across 5 years, with a median of $75.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: EBIT slumped 395.92% in 2022, then surged 1033.81% in 2025.
• A 5-year view of EBIT shows it stood at $36.0 million in 2022, then tumbled by 60.61% to $14.2 million in 2023, then jumped by 434.02% to $75.8 million in 2024, then jumped by 47.81% to $112.0 million in 2025, then increased by 26.54% to $141.8 million in 2026.
• The last three EBIT figures came in at $141.8 million (Q1 2026), $112.0 million (Q4 2025), and $70.3 million (Q3 2025), per Business Quant data.